Mosaic Therapeutics Strengthens Leadership with Appointment of Dr. Vince O’Neill as Head of R&D
Mosaic Therapeutics, a clinical-stage oncology company focused on developing next-generation combination therapies, has announced the appointment of Dr. Vince O’Neill, MD, as its new Head of Research and Development (R&D). The move marks a significant step in the company’s strategic expansion as it advances its pipeline of precision oncology treatments.
A Strategic Appointment at a Pivotal Time
Mosaic Therapeutics is entering a critical phase of growth, with increasing emphasis on progressing its innovative drug combination programs into clinical development. The appointment of Dr. Vince O’Neill comes at a time when the company is intensifying efforts to build out its early-stage pipeline and strengthen its scientific and clinical capabilities.
CEO Thomas Fuchs highlighted the importance of this leadership addition, noting that Dr. O’Neill’s expertise aligns closely with Mosaic’s mission to deliver transformative therapies for cancer patients. His extensive background in oncology drug development and diagnostics is expected to play a key role in shaping the company’s R&D strategy and accelerating its progress.
Leadership to Drive Innovation in Oncology
As Head of R&D, Dr. O’Neill will oversee Mosaic’s research and development activities, with a particular focus on advancing its proprietary combination therapy programs. These programs are built on the company’s “Synergistic Precision” approach, which aims to identify and develop drug combinations that work together more effectively than single-agent therapies.
A core part of his role will involve guiding the transition of promising candidates from preclinical research into clinical trials. Additionally, he will lead efforts to expand Mosaic’s early-stage pipeline, ensuring a steady flow of innovative therapies targeting unmet needs in oncology.
Extensive Experience Across the Drug Development Lifecycle
Dr. O’Neill brings more than 20 years of experience in the biotechnology and pharmaceutical industries. He is a board-certified medical oncologist with a strong track record spanning the full drug development continuum—from early discovery and Investigational New Drug (IND) applications through to regulatory approvals, including NDA (New Drug Application), BLA (Biologics License Application), and MAA (Marketing Authorization Application).
His career reflects deep involvement in both therapeutic and diagnostic development, giving him a unique perspective on integrating biomarker strategies into oncology drug development. This expertise is particularly relevant to Mosaic’s focus on precision medicine, where identifying the right patient populations is critical to treatment success.
Proven Track Record in Biotech and Pharma Leadership
Prior to joining Mosaic Therapeutics, Dr. O’Neill held several senior leadership roles across biotech companies and large pharmaceutical organizations.
Most recently, he served as Executive Vice President, Head of Product Development, and Chief Medical Officer at BioXcel Therapeutics. In this role, he was responsible for overseeing clinical development programs and guiding products through regulatory pathways.
He also served as Chief R&D Officer at OnkosXcel Therapeutics and held Chief Medical Officer positions at MIRNA Therapeutics and Exosome Diagnostics. These roles further strengthened his expertise in oncology innovation and translational medicine.
Earlier in his career, Dr. O’Neill held senior clinical and medical leadership roles at major pharmaceutical companies, including Sanofi-Aventis, GlaxoSmithKline (GSK), Genentech, and Roche. During this time, he contributed to the development and commercialization of several high-impact oncology therapies.
Contributions to Landmark Oncology Therapies
Dr. O’Neill has been involved in the development of multiple widely recognized cancer treatments, including Avastin, Venclexta, Tarceva, Mekinist, and Tafinlar. These therapies have had a significant impact on the treatment landscape for various cancers, improving outcomes for patients worldwide.
His experience working on such therapies underscores his ability to navigate complex clinical development programs and bring innovative treatments to market. This background is expected to be invaluable as Mosaic Therapeutics seeks to replicate similar successes with its own pipeline.
Expertise in Financing and Company Growth
In addition to his scientific and clinical expertise, Dr. O’Neill has demonstrated strong capabilities in corporate leadership and fundraising. During his time in early-stage biotech companies, he played a key role in securing substantial financing, including $420 million in public funding and $65 million in private Series B investment rounds.
This experience will be particularly beneficial for Mosaic as it continues to scale its operations and invest in research and development. His ability to align scientific innovation with strategic business objectives is expected to support the company’s long-term growth.
Academic and Medical Background
Dr. O’Neill holds a Bachelor of Science (BSc), Doctor of Medicine (MD), and Bachelor of Medicine, Bachelor of Surgery (MBChB) from the University of Glasgow. His medical training and clinical background as an oncologist provide a strong foundation for his work in developing patient-centered therapies.
His dual perspective as both a clinician and industry leader enables him to bridge the gap between scientific discovery and real-world patient needs—an essential quality in modern oncology drug development.
Advancing Mosaic’s Vision for Precision Medicine
Mosaic Therapeutics is focused on developing combination therapies that leverage biological insights to enhance treatment efficacy. By combining multiple agents in a targeted manner, the company aims to overcome resistance mechanisms and improve outcomes compared to traditional single-drug approaches.
Dr. O’Neill emphasized his enthusiasm for joining Mosaic at this stage, expressing his commitment to advancing the company’s programs into clinical trials. He also highlighted the importance of innovative biomarker strategies in maximizing patient benefit, aligning with Mosaic’s precision medicine approach.
With Dr. O’Neill now leading R&D, Mosaic Therapeutics is well-positioned to accelerate its pipeline and expand its impact in the oncology space. His appointment signals the company’s commitment to scientific excellence and its ambition to deliver next-generation therapies to patients with cancer.
As the company continues to grow, the combination of strong leadership, innovative science, and a clear strategic vision is expected to drive meaningful progress in the development of novel cancer treatments.
The appointment of Dr. Vince O’Neill represents a significant milestone for Mosaic Therapeutics. His extensive experience, proven leadership, and deep expertise in oncology drug development make him a valuable addition to the executive team. As Mosaic advances its mission to develop synergistic precision therapies, his leadership is likely to play a central role in shaping the company’s future and bringing new hope to patients worldwide.
About Mosaic Therapeutics
Mosaic Therapeutics is an oncology therapeutics company building the category leader in Synergistic Precision Oncology. The company’s mission is to tackle cancers with substantial unmet need and few targeted treatment options, by applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations.
Born out of pioneering research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, Mosaic has active programs across a variety of oncology indications and disease biology pathways.
The Company’s pipeline is anchored by ASTX295, an MDM2 antagonist, and ASTX029, an ERK1/2 inhibitor, both in-licensed from Astex Pharmaceuticals in April 2025. Mosaic’s first clinical combination study is expected to commence in early 2027.
